August 8, 2017

Fibralign Corporation (“Fibralign”), a developer of advanced therapeutic medical devices, announced today that the first surgery has been performed in a clinical study of secondary lymphedema treatment being conducted at Stanford University. This investigator-initiated...

May 24, 2017

Fibralign Corporation, a developer of advanced therapeutic medical devices, announces the appointment of Dimitris Dionysiou, Ph.D., M.D. as its Chief Medical Officer.  Dr. Dionysiou joins the Company during the clinical phase for its first product, the BioBridge® Colla...

September 1, 2016

Fibralign Corporation announced that Stanford University has started enrollment in its investigator-led clinical study to evaluate the efficacy of a new surgical device for treating secondary lymphedema.

The trial will evaluate the effectiveness of Fibralign’s BioBri...

April 8, 2016

Wins $30,000 first place prize among >150 amazing startups in CA event held April 7th at Stanford Medical school. Sponsored by BioSciKin, a Chinese biotech venture focused on precision medicine.

See full article at http://califesciences.org/bioscikin-1/....

July 1, 2014

Fibralign won the prestigious Medtech Innovator award at the 2014 WSGRC Medical Device Conference, placing first out of 267 startups for this top honor and $125,000 prize.

Please reload

WHO WE ARE

Fibralign Corporation is a developer of advanced therapeutic devices that utilizes Nanoweave ®, a proprietary scaffolding technology for addressing unmet medical needs.

Read More >

QUICK LINKS
GET IN TOUCH